adjuvant therapies - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.06 [0.87, 1.30]< 10%2 studies (2/-)27.8 %some concernnot evaluable moderatecrucial-
clinical improvement 0.87 [0.70, 1.08]> 10%1 study (1/-)10.4 %some concernnot evaluable moderateimportant-
Major thrombotic events or death 0.95 [0.74, 1.22]< 10%1 study (1/-)66.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

Major bleeding 1.43 [0.74, 2.74]< 10%2 studies (2/-)14.4 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 1.07 [0.76, 1.49]< 10%1 study (1/-)35.2 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.